Allogene Therapeutics, Inc. Common Stock (ALLO)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Allogene Therapeutics, Inc. Common Stock (ALLO) is listed on Nasdaq, where it has traded since October 11, 2018.
- Listed On
- Nasdaq
- Listed Since
- October 11, 2018
- Employees
- 152
- Market Cap
- $570M
About Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 203 institutions reported holding ALLO, with 311.9 million shares worth $650.5 million in aggregate. The largest reported holder was BlackRock, with 30.1 million shares worth $62.7 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 30,146,963 | $63M | Added 57.91% |
| Frazier Life Sciences Management, | 22,446,668 | $47M | Added 491.22% |
| Pfizer | 22,032,040 | $47M | Unchanged |
| State Street | 19,025,826 | $40M | Added 119.69% |
| Tpg GP a | 18,716,306 | $39M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ALLO?
Allogene Therapeutics, Inc. Common Stock (ALLO) is listed on Nasdaq, where it has traded since October 11, 2018.
Who are the largest institutional holders of ALLO?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ALLO were BlackRock, Frazier Life Sciences Management, and Pfizer.
How many institutions own ALLO?
203 institutions reported a position in ALLO for the quarter ended June 30, 2026, worth $650.5 million in total.
Did institutions buy or sell ALLO last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ALLO.
Every reported institutional holder, plus insider and congressional trades in ALLO, on SentiSense.